An Open-label Study of Cizutamig in Refractory Seropositive Rheumatoid Arthritis

This study is testing a new drug called cizutamig for people with seropositive rheumatoid arthritis (RA) — a type of joint inflammation where certain antibodies are detected in the blood — whose disease hasn't been controlled by existing biologic or targeted synthetic medications. **You may be eligible if...** - You are between 18 and 75 years old - You have been diagnosed with rheumatoid arthritis and your blood tests are positive for RF or ACPA antibodies - Your RA is moderately to severely active - You have already tried and failed or couldn't tolerate at least one advanced RA medication (biologic or targeted synthetic DMARD) **You may NOT be eligible if...** - Your blood test results are outside the safe range for this study - You have an active infection - You received a live vaccine within the past 4 weeks - You have other serious conditions that could affect participation or safety Talk to your doctor to see if this trial is right for you.